Canopy is a pre-clinical stage biotech developing a new class of biologics that will allow the elimination of antigen-specific immunity, providing non-immunosuppressive, potentially curing treatments to many dozens of autoimmune, allergic, and other antibody-mediated conditions using its proprietary Reverse-Immunization platform.